Vasospastic phenomena in patients treated with beta-adrenoceptor blocking agents.
Twenty-one patients developed Raynaud's phenomenon during treatment with beta-adrenoceptor blocking agents. The vasospastic symptoms were obviously related to the treatment, but their pathogenesis is still controversial. A decrease in cardiac output might explain the phenomenon. According to our very preliminary data an alpha-adrenergic dominance caused by a direct effect on the peripheral circulation seems more probable. Vasospastic symptoms may arise after treatment with both cardioselective and non-selective beta blocking agents. Cautious prescription of beta blocking drugs to patients with preexisting peripheral vascular disease is recommended.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000526:Alprenolol / Q000009:adverse effects; D001775:Blood Circulation / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000009:adverse effects; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects; D011928:Raynaud Disease / Q000139:chemically induced*; D012881:Skin Temperature / Q000187:drug effects; D013999:Timolol / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D008790:Metoprolol